Issuing more shares is not a good thing. The reason it is needed is to raise capital to get the product into manufacturing which is expensive. I do not believe DVAX has the capital to do this. They can raise the capital by loaning money and repaying the funds plus interest. Or they can dilute which does not cost them anything. If you believe DVAX cares about the price per share, you are mistaken. This is a perfect time for the company to dilute because interest is high and momentum is building. The capital raise would be very easy. I am hoping it does not happen in the near future but you cannot predict this event. I have been burnt on this stock when the FDA required a more extensive study. There were winners and losers. Timing is everything. I have bought back in since it was in the $5 and I am recouping some of my losses. I am hopeful dilution is delayed but I do believe it is inevitable. Hopefully I can reach my break even point. Some have made a lot and some have lost, on a pretty promising hepatitis immunization that would help patients. Also, sometimes the hype of a drug coming to market creates more profit for an investor than the pps per share once it finally does. Seems unusual a large drug company has not bought them out. Unless DVAX wants to go it alone. A buyout would increase your profit on this investment. DVAX going it alone could result in dilution and your returns may not be as high as you would like. Would be nice to be a mind reader as nobody truly knows what is happening except the insiders. Watch for a huge shift in a downward pps. Tells you something is up before it finally becomes public. Go DVAX!
News 
Market Data 
Discover 
